ES2347593T3 - Nuevos derivados ciclicos sustituidos de furopirimidina y su uso para el tratamiento de enfermedades cardiobasculares. - Google Patents

Info

Publication number

ES2347593T3

ES2347593T3 ES06840964T ES06840964T ES2347593T3 ES 2347593 T3 ES2347593 T3 ES 2347593T3 ES 06840964 T ES06840964 T ES 06840964T ES 06840964 T ES06840964 T ES 06840964T ES 2347593 T3 ES2347593 T3 ES 2347593T3

Authority

ES

Spain

Prior art keywords

amino

alkyl

mmol

formula

group

Prior art date

2005-12-21

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 238000011282 treatment Methods 0.000 title claims description 18
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 14
• 201000010099 disease Diseases 0.000 title claims description 12
• -1 1H-tetrazol-5-yl Chemical group 0.000 claims abstract description 115
• 150000003839 salts Chemical class 0.000 claims abstract description 47
• 239000012453 solvate Substances 0.000 claims abstract description 40
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 38
• 229910052731 fluorine Inorganic materials 0.000 claims abstract description 37
• 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 29
• 229910052760 oxygen Inorganic materials 0.000 claims abstract description 29
• 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract description 28
• 229910052801 chlorine Inorganic materials 0.000 claims abstract description 23
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 23
• 125000000217 alkyl group Chemical group 0.000 claims abstract description 19
• 125000002252 acyl group Chemical group 0.000 claims abstract description 18
• 125000003545 alkoxy group Chemical group 0.000 claims abstract description 14
• 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 13
• 125000003342 alkenyl group Chemical group 0.000 claims abstract description 11
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract description 8
• 125000000304 alkynyl group Chemical group 0.000 claims abstract description 6
• 229910052717 sulfur Inorganic materials 0.000 claims abstract description 5
• 238000000034 method Methods 0.000 claims description 255
• 150000001875 compounds Chemical class 0.000 claims description 231
• 239000001257 hydrogen Substances 0.000 claims description 61
• 229910052739 hydrogen Inorganic materials 0.000 claims description 61
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 40
• 125000004432 carbon atom Chemical group C* 0.000 claims description 38
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 36
• 239000011737 fluorine Substances 0.000 claims description 36
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 28
• 239000002253 acid Substances 0.000 claims description 27
• 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 25
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 24
• 239000000460 chlorine Substances 0.000 claims description 23
• 239000012442 inert solvent Substances 0.000 claims description 23
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 22
• 239000002904 solvent Substances 0.000 claims description 21
• 239000003054 catalyst Substances 0.000 claims description 20
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
• 150000001335 aliphatic alkanes Chemical class 0.000 claims description 19
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
• 229910052763 palladium Inorganic materials 0.000 claims description 18
• 238000002360 preparation method Methods 0.000 claims description 18
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 17
• 230000027455 binding Effects 0.000 claims description 17
• 125000001424 substituent group Chemical group 0.000 claims description 17
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 16
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
• 150000001336 alkenes Chemical class 0.000 claims description 14
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 13
• 150000002148 esters Chemical class 0.000 claims description 13
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims description 12
• 239000003814 drug Substances 0.000 claims description 10
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 10
• 238000011321 prophylaxis Methods 0.000 claims description 9
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
• 229910052736 halogen Inorganic materials 0.000 claims description 8
• 150000002367 halogens Chemical class 0.000 claims description 8
• 125000001072 heteroaryl group Chemical group 0.000 claims description 8
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 8
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
• 101100132433 Arabidopsis thaliana VIII-1 gene Proteins 0.000 claims description 7
• 101100459319 Arabidopsis thaliana VIII-2 gene Proteins 0.000 claims description 7
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
• 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 6
• 125000003386 piperidinyl group Chemical group 0.000 claims description 6
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
• 150000007513 acids Chemical class 0.000 claims description 5
• 239000004480 active ingredient Substances 0.000 claims description 5
• 150000001735 carboxylic acids Chemical class 0.000 claims description 5
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
• 230000007062 hydrolysis Effects 0.000 claims description 5
• 238000006460 hydrolysis reaction Methods 0.000 claims description 5
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 5
• 229920002554 vinyl polymer Polymers 0.000 claims description 5
• 125000006823 (C1-C6) acyl group Chemical group 0.000 claims description 4
• 239000002671 adjuvant Substances 0.000 claims description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
• 229940079593 drug Drugs 0.000 claims description 4
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
• 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
• 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 3
• 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims description 3
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 3
• 125000002757 morpholinyl group Chemical group 0.000 claims description 3
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
• 231100000252 nontoxic Toxicity 0.000 claims description 3
• 230000003000 nontoxic effect Effects 0.000 claims description 3
• 230000008569 process Effects 0.000 claims description 3
• 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
• 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 2
• 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
• 108091006335 Prostaglandin I receptors Proteins 0.000 abstract description 7
• 230000000694 effects Effects 0.000 abstract description 7
• CBIWCJGTVQGGIQ-UHFFFAOYSA-N 2-[3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(NC=3C=C(OCC(O)=O)C=CC=3)=C12 CBIWCJGTVQGGIQ-UHFFFAOYSA-N 0.000 abstract description 6
• 239000003146 anticoagulant agent Substances 0.000 abstract description 4
• 125000004414 alkyl thio group Chemical group 0.000 abstract description 3
• 229940127219 anticoagulant drug Drugs 0.000 abstract description 3
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract description 2
• 239000012190 activator Substances 0.000 abstract description 2
• 125000004442 acylamino group Chemical group 0.000 abstract description 2
• 102000009079 Epoprostenol Receptors Human genes 0.000 abstract 2
• JUQAECQBUNODQP-UHFFFAOYSA-N furo[3,2-d]pyrimidine Chemical class C1=NC=C2OC=CC2=N1 JUQAECQBUNODQP-UHFFFAOYSA-N 0.000 abstract 2
• 208000001953 Hypotension Diseases 0.000 abstract 1
• 230000003257 anti-anginal effect Effects 0.000 abstract 1
• 230000001966 cerebroprotective effect Effects 0.000 abstract 1
• 125000001475 halogen functional group Chemical group 0.000 abstract 1
• 230000002439 hemostatic effect Effects 0.000 abstract 1
• 208000021822 hypotensive Diseases 0.000 abstract 1
• 230000001077 hypotensive effect Effects 0.000 abstract 1
• 238000004519 manufacturing process Methods 0.000 abstract 1
• 230000010534 mechanism of action Effects 0.000 abstract 1
• 238000001525 receptor binding assay Methods 0.000 abstract 1
• YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 373
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 294
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 281
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 181
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 180
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 177
• 239000000203 mixture Substances 0.000 description 173
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 166
• 238000005160 1H NMR spectroscopy Methods 0.000 description 157
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 147
• 239000000243 solution Substances 0.000 description 133
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 100
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 92
• HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 92
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 90
• 239000000047 product Substances 0.000 description 90
• 239000007787 solid Substances 0.000 description 87
• 238000001816 cooling Methods 0.000 description 86
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 85
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 81
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 78
• 239000012074 organic phase Substances 0.000 description 74
• 239000012071 phase Substances 0.000 description 73
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 72
• 235000002639 sodium chloride Nutrition 0.000 description 70
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 66
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 62
• 239000003480 eluent Substances 0.000 description 62
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 58
• 238000006243 chemical reaction Methods 0.000 description 46
• AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 44
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 44
• 239000011541 reaction mixture Substances 0.000 description 43
• UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 43
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 38
• 238000004128 high performance liquid chromatography Methods 0.000 description 37
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 36
• 239000011780 sodium chloride Substances 0.000 description 36
• 238000003756 stirring Methods 0.000 description 36
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 36
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 34
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
• 238000010992 reflux Methods 0.000 description 34
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 32
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 32
• 239000000706 filtrate Substances 0.000 description 32
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 32
• 235000019341 magnesium sulphate Nutrition 0.000 description 32
• 238000010898 silica gel chromatography Methods 0.000 description 32
• 235000011121 sodium hydroxide Nutrition 0.000 description 32
• 229910052938 sodium sulfate Inorganic materials 0.000 description 32
• 235000011152 sodium sulphate Nutrition 0.000 description 32
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 30
• 239000012043 crude product Substances 0.000 description 30
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 29
• 235000019253 formic acid Nutrition 0.000 description 29
• ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 28
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 28
• 239000002585 base Substances 0.000 description 28
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 26
• 239000000725 suspension Substances 0.000 description 26
• 239000000741 silica gel Substances 0.000 description 25
• 229910002027 silica gel Inorganic materials 0.000 description 25
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 23
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 23
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
• NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 21
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
• 239000003112 inhibitor Substances 0.000 description 19
• 238000000746 purification Methods 0.000 description 19
• 238000001914 filtration Methods 0.000 description 18
• 235000017557 sodium bicarbonate Nutrition 0.000 description 18
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 18
• 239000007858 starting material Substances 0.000 description 18
• FFAVCNPTHSRQCU-UHFFFAOYSA-N 4-chloro-5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(Cl)=C12 FFAVCNPTHSRQCU-UHFFFAOYSA-N 0.000 description 17
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
• 239000012298 atmosphere Substances 0.000 description 16
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 16
• KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 16
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 15
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
• 239000008346 aqueous phase Substances 0.000 description 15
• SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 15
• CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 15
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
• 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 14
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 14
• 229910052796 boron Inorganic materials 0.000 description 13
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
• 150000002431 hydrogen Chemical class 0.000 description 12
• 239000003208 petroleum Substances 0.000 description 12
• 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 11
• 229910052786 argon Inorganic materials 0.000 description 11
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 11
• 229960004592 isopropanol Drugs 0.000 description 11
• 238000000825 ultraviolet detection Methods 0.000 description 11
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 10
• 239000005557 antagonist Substances 0.000 description 10
• CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 10
• GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 10
• 239000003921 oil Substances 0.000 description 10
• 239000011734 sodium Substances 0.000 description 10
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 10
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
• 150000001412 amines Chemical class 0.000 description 9
• 235000019270 ammonium chloride Nutrition 0.000 description 9
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 9
• 229910000024 caesium carbonate Inorganic materials 0.000 description 9
• 238000001514 detection method Methods 0.000 description 9
• 238000002347 injection Methods 0.000 description 9
• 239000007924 injection Substances 0.000 description 9
• 238000002953 preparative HPLC Methods 0.000 description 9
• 150000001298 alcohols Chemical class 0.000 description 8
• 230000015572 biosynthetic process Effects 0.000 description 8
• 229950005499 carbon tetrachloride Drugs 0.000 description 8
• 238000004587 chromatography analysis Methods 0.000 description 8
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 8
• WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
• 150000004702 methyl esters Chemical class 0.000 description 8
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 8
• 229910000029 sodium carbonate Inorganic materials 0.000 description 8
• BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 8
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
• 239000013078 crystal Substances 0.000 description 7
• FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 7
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 6
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 6
• 239000005909 Kieselgur Substances 0.000 description 6
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
• 150000001540 azides Chemical class 0.000 description 6
• 239000003613 bile acid Substances 0.000 description 6
• 239000007853 buffer solution Substances 0.000 description 6
• 239000012141 concentrate Substances 0.000 description 6
• 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 6
• QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 6
• 238000000926 separation method Methods 0.000 description 6
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
• SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 6
• WHNQTHDJEZTVHS-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)propanoic acid Chemical compound C1=CC=C2SC(CCC(=O)O)=NC2=C1 WHNQTHDJEZTVHS-UHFFFAOYSA-N 0.000 description 5
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 5
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
• 238000005481 NMR spectroscopy Methods 0.000 description 5
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
• 229910021529 ammonia Inorganic materials 0.000 description 5
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 238000010908 decantation Methods 0.000 description 5
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
• 150000002170 ethers Chemical class 0.000 description 5
• 125000004494 ethyl ester group Chemical group 0.000 description 5
• 239000007789 gas Substances 0.000 description 5
• PSVNEMZOHPSMTL-UHFFFAOYSA-N methyl 2-[3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenoxy]acetate Chemical compound COC(=O)COC1=CC=CC(NC=2C=3C(C=4C=CC(OC)=CC=4)=C(OC=3N=CN=2)C=2C=CC=CC=2)=C1 PSVNEMZOHPSMTL-UHFFFAOYSA-N 0.000 description 5
• KQEVIFKPZOGBMZ-UHFFFAOYSA-N methyl 3-bromopropanoate Chemical compound COC(=O)CCBr KQEVIFKPZOGBMZ-UHFFFAOYSA-N 0.000 description 5
• 229910052757 nitrogen Inorganic materials 0.000 description 5
• 239000011591 potassium Substances 0.000 description 5
• 229960003975 potassium Drugs 0.000 description 5
• 229910000027 potassium carbonate Inorganic materials 0.000 description 5
• 235000017550 sodium carbonate Nutrition 0.000 description 5
• 229910000104 sodium hydride Inorganic materials 0.000 description 5
• PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 4
• YCCSINZUTAAEEG-UHFFFAOYSA-N 5-(4-methoxyphenyl)-6-phenyl-4-piperidin-3-yloxyfuro[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(OC3CNCCC3)=C12 YCCSINZUTAAEEG-UHFFFAOYSA-N 0.000 description 4
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
• 239000011575 calcium Substances 0.000 description 4
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 4
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 4
• CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
• 238000007865 diluting Methods 0.000 description 4
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 238000003818 flash chromatography Methods 0.000 description 4
• 229930195733 hydrocarbon Natural products 0.000 description 4
• 150000002430 hydrocarbons Chemical class 0.000 description 4
• QAWFLJGZSZIZHO-UHFFFAOYSA-N methyl 4-bromobutanoate Chemical compound COC(=O)CCCBr QAWFLJGZSZIZHO-UHFFFAOYSA-N 0.000 description 4
• KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 description 4
• 150000002825 nitriles Chemical class 0.000 description 4
• 238000007911 parenteral administration Methods 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 239000002244 precipitate Substances 0.000 description 4
• 235000019260 propionic acid Nutrition 0.000 description 4
• 239000013049 sediment Substances 0.000 description 4
• 239000012312 sodium hydride Substances 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 238000000967 suction filtration Methods 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
• 239000008096 xylene Substances 0.000 description 4
• UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 4
• GGMOFYAZFUVRJA-OALUTQOASA-N (1s,3s)-3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]cyclohexan-1-ol Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(N[C@@H]3C[C@@H](O)CCC3)=C12 GGMOFYAZFUVRJA-OALUTQOASA-N 0.000 description 3
• YVEWWGLOIVPVLD-UHFFFAOYSA-N 2-(2-fluorophenyl)-2-hydroxy-1-(4-methoxyphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1C(=O)C(O)C1=CC=CC=C1F YVEWWGLOIVPVLD-UHFFFAOYSA-N 0.000 description 3
• DHEFGKJWEPVLHP-UHFFFAOYSA-N 2-(4-ethylphenyl)-2-trimethylsilyloxyacetonitrile Chemical compound CCC1=CC=C(C(O[Si](C)(C)C)C#N)C=C1 DHEFGKJWEPVLHP-UHFFFAOYSA-N 0.000 description 3
• FSTVFVKWUVIRLF-UHFFFAOYSA-N 2-(4-methoxyphenyl)-2-trimethylsilyloxyacetonitrile Chemical compound COC1=CC=C(C(O[Si](C)(C)C)C#N)C=C1 FSTVFVKWUVIRLF-UHFFFAOYSA-N 0.000 description 3
• UWTDTJWGYWUILP-UHFFFAOYSA-N 2-amino-5-phenylfuran-3-carbonitrile Chemical compound N#CC1=C(N)OC(C=2C=CC=CC=2)=C1 UWTDTJWGYWUILP-UHFFFAOYSA-N 0.000 description 3
• QIOHIZXGHJZTNI-UHFFFAOYSA-N 3-[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxyphenol Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(OC=3C=C(O)C=CC=3)=C12 QIOHIZXGHJZTNI-UHFFFAOYSA-N 0.000 description 3
• WWQPJSOHSIWQNE-UHFFFAOYSA-N 5-bromo-4-chloro-6-phenylfuro[2,3-d]pyrimidine Chemical compound BrC=1C=2C(Cl)=NC=NC=2OC=1C1=CC=CC=C1 WWQPJSOHSIWQNE-UHFFFAOYSA-N 0.000 description 3
• 239000005541 ACE inhibitor Substances 0.000 description 3
• NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 3
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
• 102000015427 Angiotensins Human genes 0.000 description 3
• 108010064733 Angiotensins Proteins 0.000 description 3
• 229940127291 Calcium channel antagonist Drugs 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 102000004895 Lipoproteins Human genes 0.000 description 3
• 108090001030 Lipoproteins Proteins 0.000 description 3
• 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 3
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
• NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
• 239000003463 adsorbent Substances 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 235000011114 ammonium hydroxide Nutrition 0.000 description 3
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
• 239000003705 antithrombocytic agent Substances 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 239000002876 beta blocker Substances 0.000 description 3
• YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 3
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
• 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000002425 crystallisation Methods 0.000 description 3
• 230000008025 crystallization Effects 0.000 description 3
• 238000007257 deesterification reaction Methods 0.000 description 3
• SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 3
• 239000002934 diuretic Substances 0.000 description 3
• 238000001035 drying Methods 0.000 description 3
• WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 3
• 150000008282 halocarbons Chemical class 0.000 description 3
• 239000001307 helium Substances 0.000 description 3
• 229910052734 helium Inorganic materials 0.000 description 3
• SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 3
• 125000005842 heteroatom Chemical group 0.000 description 3
• 239000008241 heterogeneous mixture Substances 0.000 description 3
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
• 150000004679 hydroxides Chemical class 0.000 description 3
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
• 150000007529 inorganic bases Chemical class 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 238000004949 mass spectrometry Methods 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• XENTXTUUBRDTST-UHFFFAOYSA-N methyl 2-(3-aminophenoxy)acetate Chemical compound COC(=O)COC1=CC=CC(N)=C1 XENTXTUUBRDTST-UHFFFAOYSA-N 0.000 description 3
• DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 3
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000009103 reabsorption Effects 0.000 description 3
• 229940044601 receptor agonist Drugs 0.000 description 3
• 239000000018 receptor agonist Substances 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 239000002461 renin inhibitor Substances 0.000 description 3
• 229940086526 renin-inhibitors Drugs 0.000 description 3
• 239000003590 rho kinase inhibitor Substances 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 159000000000 sodium salts Chemical class 0.000 description 3
• 102000004217 thyroid hormone receptors Human genes 0.000 description 3
• 108090000721 thyroid hormone receptors Proteins 0.000 description 3
• NWUBSQHKCFENQU-STQMWFEESA-N (1s,3s)-3-(5-bromo-6-phenylfuro[2,3-d]pyrimidin-4-yl)oxycyclohexan-1-ol Chemical compound C1[C@@H](O)CCC[C@@H]1OC1=NC=NC2=C1C(Br)=C(C=1C=CC=CC=1)O2 NWUBSQHKCFENQU-STQMWFEESA-N 0.000 description 2
• NIQIPYGXPZUDDP-WDSKDSINSA-N (1s,3s)-3-aminocyclohexan-1-ol Chemical compound N[C@H]1CCC[C@H](O)C1 NIQIPYGXPZUDDP-WDSKDSINSA-N 0.000 description 2
• UTTCOAGPVHRUFO-GFCCVEGCSA-N (3r)-1-benzylpiperidin-3-ol Chemical compound C1[C@H](O)CCCN1CC1=CC=CC=C1 UTTCOAGPVHRUFO-GFCCVEGCSA-N 0.000 description 2
• QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
• WRRJGNJTEXPFDV-JXMROGBWSA-N 1-[(z)-2-chloro-2-nitroethenyl]-4-ethylbenzene Chemical compound CCC1=CC=C(\C=C(/Cl)[N+]([O-])=O)C=C1 WRRJGNJTEXPFDV-JXMROGBWSA-N 0.000 description 2
• GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
• LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
• IZVGYNLANPSHAD-UHFFFAOYSA-N 2-[3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenoxy]acetonitrile Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(NC=3C=C(OCC#N)C=CC=3)=C12 IZVGYNLANPSHAD-UHFFFAOYSA-N 0.000 description 2
• OGZNHJMOIZUHOM-UHFFFAOYSA-N 2-amino-4-(4-ethylphenyl)-5-(2-fluorophenyl)furan-3-carbonitrile Chemical compound C1=CC(CC)=CC=C1C1=C(C=2C(=CC=CC=2)F)OC(N)=C1C#N OGZNHJMOIZUHOM-UHFFFAOYSA-N 0.000 description 2
• WLBQOSMQPBWVMG-UHFFFAOYSA-N 2-amino-4-(4-ethylphenyl)-5-phenylfuran-3-carbonitrile Chemical compound C1=CC(CC)=CC=C1C1=C(C=2C=CC=CC=2)OC(N)=C1C#N WLBQOSMQPBWVMG-UHFFFAOYSA-N 0.000 description 2
• AQDOQNFBMSFEFQ-UHFFFAOYSA-N 2-amino-4-(4-methoxyphenyl)-5-phenylfuran-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC(N)=C1C#N AQDOQNFBMSFEFQ-UHFFFAOYSA-N 0.000 description 2
• QNGBQONBZBPFQI-UHFFFAOYSA-N 2-amino-4-phenylfuran-3-carbonitrile Chemical compound N#CC1=C(N)OC=C1C1=CC=CC=C1 QNGBQONBZBPFQI-UHFFFAOYSA-N 0.000 description 2
• SVVHMWQFUQUPEI-UHFFFAOYSA-N 2-amino-5-(2-fluorophenyl)-4-(4-methoxyphenyl)furan-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC=CC=2)F)OC(N)=C1C#N SVVHMWQFUQUPEI-UHFFFAOYSA-N 0.000 description 2
• ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 2
• PVSFIFPJPUEHPO-UHFFFAOYSA-N 2-hydroxy-1-(4-methoxyphenyl)-2-phenylethanone Chemical compound C1=CC(OC)=CC=C1C(=O)C(O)C1=CC=CC=C1 PVSFIFPJPUEHPO-UHFFFAOYSA-N 0.000 description 2
• BDLLWACTRQJNEY-UHFFFAOYSA-N 3-[3-[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxypiperidin-1-yl]propanenitrile Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(OC3CN(CCC#N)CCC3)=C12 BDLLWACTRQJNEY-UHFFFAOYSA-N 0.000 description 2
• MMCFUQAMYCOOOS-UHFFFAOYSA-N 3-[3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenyl]propanoic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(NC=3C=C(CCC(O)=O)C=CC=3)=C12 MMCFUQAMYCOOOS-UHFFFAOYSA-N 0.000 description 2
• BMEYKDLERSTXGC-UHFFFAOYSA-N 3-[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxyaniline Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(OC=3C=C(N)C=CC=3)=C12 BMEYKDLERSTXGC-UHFFFAOYSA-N 0.000 description 2
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
• MOARJWRQONRRDO-UHFFFAOYSA-N 4-chloro-5-(4-ethylphenyl)-6-(2-fluorophenyl)furo[2,3-d]pyrimidine Chemical compound C1=CC(CC)=CC=C1C1=C(C=2C(=CC=CC=2)F)OC2=NC=NC(Cl)=C12 MOARJWRQONRRDO-UHFFFAOYSA-N 0.000 description 2
• IXKZXFQULLZVQJ-UHFFFAOYSA-N 4-chloro-5-phenylfuro[2,3-d]pyrimidine Chemical compound C1=2C(Cl)=NC=NC=2OC=C1C1=CC=CC=C1 IXKZXFQULLZVQJ-UHFFFAOYSA-N 0.000 description 2
• WIYLTURAZAOGIR-UHFFFAOYSA-N 4-chloro-6-(2-fluorophenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC=CC=2)F)OC2=NC=NC(Cl)=C12 WIYLTURAZAOGIR-UHFFFAOYSA-N 0.000 description 2
• BMPUSSWCLJQHOR-UHFFFAOYSA-N 4-chloro-6-phenylfuro[2,3-d]pyrimidine Chemical compound C=1C=2C(Cl)=NC=NC=2OC=1C1=CC=CC=C1 BMPUSSWCLJQHOR-UHFFFAOYSA-N 0.000 description 2
• PEFVPWSISZURQJ-UHFFFAOYSA-N 5,6-diphenyl-3h-furo[2,3-d]pyrimidin-4-one Chemical compound C1=2C(=O)NC=NC=2OC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 PEFVPWSISZURQJ-UHFFFAOYSA-N 0.000 description 2
• BAAMAQJLLHYXOO-UHFFFAOYSA-N 5-(4-ethylphenyl)-3h-furo[2,3-d]pyrimidin-4-one Chemical compound C1=CC(CC)=CC=C1C1=COC2=C1C(=O)NC=N2 BAAMAQJLLHYXOO-UHFFFAOYSA-N 0.000 description 2
• ZPSWIPRUDRQJMH-UHFFFAOYSA-N 5-(4-ethylphenyl)-6-(2-fluorophenyl)-3h-furo[2,3-d]pyrimidin-4-one Chemical compound C1=CC(CC)=CC=C1C1=C(C=2C(=CC=CC=2)F)OC2=C1C(=O)NC=N2 ZPSWIPRUDRQJMH-UHFFFAOYSA-N 0.000 description 2
• HAIYMWMTMSBGOO-UHFFFAOYSA-N 5-(4-ethylphenyl)-6-phenyl-3h-furo[2,3-d]pyrimidin-4-one Chemical compound C1=CC(CC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=C1C(=O)NC=N2 HAIYMWMTMSBGOO-UHFFFAOYSA-N 0.000 description 2
• YBFDJZPPEKHLIQ-UHFFFAOYSA-N 5-(4-methoxyphenyl)-6-phenyl-3h-furo[2,3-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=C1C(=O)NC=N2 YBFDJZPPEKHLIQ-UHFFFAOYSA-N 0.000 description 2
• REZIBYJSFSWKFL-UHFFFAOYSA-N 5-bromo-6-phenyl-4-piperidin-3-yloxyfuro[2,3-d]pyrimidine Chemical compound C=12C(Br)=C(C=3C=CC=CC=3)OC2=NC=NC=1OC1CCCNC1 REZIBYJSFSWKFL-UHFFFAOYSA-N 0.000 description 2
• KJIBNAKAPXNJDX-UHFFFAOYSA-N 5-bromo-6-phenylfuro[2,3-d]pyrimidin-4-amine Chemical compound BrC=1C=2C(N)=NC=NC=2OC=1C1=CC=CC=C1 KJIBNAKAPXNJDX-UHFFFAOYSA-N 0.000 description 2
• AEOZQAQEYHKPNA-UHFFFAOYSA-N 5-phenyl-3h-furo[2,3-d]pyrimidin-4-one Chemical compound C1=2C(=O)NC=NC=2OC=C1C1=CC=CC=C1 AEOZQAQEYHKPNA-UHFFFAOYSA-N 0.000 description 2
• OXHAMORZOFMTEX-UHFFFAOYSA-N 6-(2-fluorophenyl)-5-(4-methoxyphenyl)-3h-furo[2,3-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC=CC=2)F)OC2=C1C(=O)NC=N2 OXHAMORZOFMTEX-UHFFFAOYSA-N 0.000 description 2
• KVIOVLRDQJNDTK-UHFFFAOYSA-N 6-phenyl-3h-furo[2,3-d]pyrimidin-4-one Chemical compound C=1C=2C(=O)NC=NC=2OC=1C1=CC=CC=C1 KVIOVLRDQJNDTK-UHFFFAOYSA-N 0.000 description 2
• KLUPXPVKDBPOMJ-UHFFFAOYSA-N 6-phenylfuro[2,3-d]pyrimidin-4-amine Chemical compound C=1C=2C(N)=NC=NC=2OC=1C1=CC=CC=C1 KLUPXPVKDBPOMJ-UHFFFAOYSA-N 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
• 102000002045 Endothelin Human genes 0.000 description 2
• 108050009340 Endothelin Proteins 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
• 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
• 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 2
• UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
• 229940127470 Lipase Inhibitors Drugs 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical compound CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• 108010016731 PPAR gamma Proteins 0.000 description 2
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
• 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 2
• 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 2
• 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
• YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
• ZLMJMSJWJFRBEC-LZFNBGRKSA-N Potassium-45 Chemical compound [45K] ZLMJMSJWJFRBEC-LZFNBGRKSA-N 0.000 description 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 230000001476 alcoholic effect Effects 0.000 description 2
• 229940083712 aldosterone antagonist Drugs 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 238000002399 angioplasty Methods 0.000 description 2
• 230000002785 anti-thrombosis Effects 0.000 description 2
• 229940114079 arachidonic acid Drugs 0.000 description 2
• 235000021342 arachidonic acid Nutrition 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000002051 biphasic effect Effects 0.000 description 2
• 239000012455 biphasic mixture Substances 0.000 description 2
• 210000001772 blood platelet Anatomy 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 238000009835 boiling Methods 0.000 description 2
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
• 244000309464 bull Species 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 229910000019 calcium carbonate Inorganic materials 0.000 description 2
• 150000001805 chlorine compounds Chemical class 0.000 description 2
• MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
• 229960001701 chloroform Drugs 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 230000001906 cholesterol absorption Effects 0.000 description 2
• 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 2
• ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
• ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical group C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 2
• RLMGYIOTPQVQJR-UHFFFAOYSA-N cyclohexane-1,3-diol Chemical compound OC1CCCC(O)C1 RLMGYIOTPQVQJR-UHFFFAOYSA-N 0.000 description 2
• 150000004683 dihydrates Chemical class 0.000 description 2
• 229940043279 diisopropylamine Drugs 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 230000006806 disease prevention Effects 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 229940030606 diuretics Drugs 0.000 description 2
• GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
• 229960001123 epoprostenol Drugs 0.000 description 2
• 235000019197 fats Nutrition 0.000 description 2
• 239000010408 film Substances 0.000 description 2
• 239000012065 filter cake Substances 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• 239000013505 freshwater Substances 0.000 description 2
• HVWJATXZZQPVEL-UHFFFAOYSA-N furo[3,2-d]pyrimidin-4-amine Chemical class NC1=NC=NC2=C1OC=C2 HVWJATXZZQPVEL-UHFFFAOYSA-N 0.000 description 2
• 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 2
• 150000003278 haem Chemical class 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• 239000005457 ice water Substances 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 229910052808 lithium carbonate Inorganic materials 0.000 description 2
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 229940098779 methanesulfonic acid Drugs 0.000 description 2
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
• CHCUMDCPLDAJOC-TVTKMGCBSA-N methyl (e)-3-[(2s,4r)-4-hydroxy-1-[(1r)-1-phenylethyl]piperidin-2-yl]prop-2-enoate Chemical compound COC(=O)\C=C\[C@@H]1C[C@H](O)CCN1[C@H](C)C1=CC=CC=C1 CHCUMDCPLDAJOC-TVTKMGCBSA-N 0.000 description 2
• KOBGHVWHICNPFH-UHFFFAOYSA-N methyl 2-(3-nitrophenoxy)acetate Chemical compound COC(=O)COC1=CC=CC([N+]([O-])=O)=C1 KOBGHVWHICNPFH-UHFFFAOYSA-N 0.000 description 2
• FUUNDKDOFSHJFO-UHFFFAOYSA-N methyl 2-[3-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]phenoxy]acetate Chemical compound COC(=O)COC1=CC=CC(NC=2C=3C(C=4C=CC=CC=4)=C(OC=3N=CN=2)C=2C=CC=CC=2)=C1 FUUNDKDOFSHJFO-UHFFFAOYSA-N 0.000 description 2
• SHKQAZKBAXRZIK-UHFFFAOYSA-N methyl 2-[3-[[5,6-bis(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]amino]phenoxy]acetate Chemical compound COC(=O)COC1=CC=CC(NC=2C=3C(C=4C=CC(OC)=CC=4)=C(OC=3N=CN=2)C=2C=CC(OC)=CC=2)=C1 SHKQAZKBAXRZIK-UHFFFAOYSA-N 0.000 description 2
• KZBYCMLGQGDZAV-UHFFFAOYSA-N methyl 2-[3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenyl]acetate Chemical compound COC(=O)CC1=CC=CC(NC=2C=3C(C=4C=CC(OC)=CC=4)=C(OC=3N=CN=2)C=2C=CC=CC=2)=C1 KZBYCMLGQGDZAV-UHFFFAOYSA-N 0.000 description 2
• QRQFQYYQJSWTAM-UHFFFAOYSA-N methyl 2-[3-[[6-(4-bromophenyl)-5-(4-fluorophenyl)furo[2,3-d]pyrimidin-4-yl]amino]phenoxy]acetate Chemical compound COC(=O)COC1=CC=CC(NC=2C=3C(C=4C=CC(F)=CC=4)=C(OC=3N=CN=2)C=2C=CC(Br)=CC=2)=C1 QRQFQYYQJSWTAM-UHFFFAOYSA-N 0.000 description 2
• YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 2
• GFSNFXRNPCKOIY-UHFFFAOYSA-N methyl 3-[3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenyl]propanoate Chemical compound COC(=O)CCC1=CC=CC(NC=2C=3C(C=4C=CC(OC)=CC=4)=C(OC=3N=CN=2)C=2C=CC=CC=2)=C1 GFSNFXRNPCKOIY-UHFFFAOYSA-N 0.000 description 2
• DXIJVAUJJPQZSN-UHFFFAOYSA-N methyl 3-[4-[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxyphenyl]propanoate Chemical compound C1=CC(CCC(=O)OC)=CC=C1OC1=NC=NC2=C1C(C=1C=CC(OC)=CC=1)=C(C=1C=CC=CC=1)O2 DXIJVAUJJPQZSN-UHFFFAOYSA-N 0.000 description 2
• BXLRVOCJXZLXBD-UHFFFAOYSA-N methyl 4-(2-nitrophenyl)butanoate Chemical compound COC(=O)CCCC1=CC=CC=C1[N+]([O-])=O BXLRVOCJXZLXBD-UHFFFAOYSA-N 0.000 description 2
• QBEDYKJZQBFOTQ-UHFFFAOYSA-N methyl 4-[2-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenyl]butanoate Chemical compound COC(=O)CCCC1=CC=CC=C1NC1=NC=NC2=C1C(C=1C=CC(OC)=CC=1)=C(C=1C=CC=CC=1)O2 QBEDYKJZQBFOTQ-UHFFFAOYSA-N 0.000 description 2
• HXKQQXLRLRPKLM-UHFFFAOYSA-N methyl 4-[3-[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxypiperidin-1-yl]butanoate Chemical compound C1N(CCCC(=O)OC)CCCC1OC1=NC=NC2=C1C(C=1C=CC(OC)=CC=1)=C(C=1C=CC=CC=1)O2 HXKQQXLRLRPKLM-UHFFFAOYSA-N 0.000 description 2
• KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• 125000004433 nitrogen atom Chemical group N* 0.000 description 2
• ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 2
• LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxy-acetic acid Natural products OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
• XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 2
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 235000011181 potassium carbonates Nutrition 0.000 description 2
• NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
• 230000000019 pro-fibrinolytic effect Effects 0.000 description 2
• FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• 150000003174 prostaglandin I2 derivatives Chemical class 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 125000003373 pyrazinyl group Chemical group 0.000 description 2
• 125000002098 pyridazinyl group Chemical group 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 125000004076 pyridyl group Chemical group 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• 150000003235 pyrrolidines Chemical class 0.000 description 2
• 125000006413 ring segment Chemical group 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
• 239000004059 squalene synthase inhibitor Substances 0.000 description 2
• 239000012258 stirred mixture Substances 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
• RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
• CSRMAOCBRDJCAZ-ZJUUUORDSA-N tert-butyl 2-[(1s,3r)-3-hydroxycyclohexyl]oxyacetate Chemical compound CC(C)(C)OC(=O)CO[C@H]1CCC[C@@H](O)C1 CSRMAOCBRDJCAZ-ZJUUUORDSA-N 0.000 description 2
• DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000001131 transforming effect Effects 0.000 description 2
• LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
• 208000019553 vascular disease Diseases 0.000 description 2
• 235000012431 wafers Nutrition 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 239000003643 water by type Substances 0.000 description 2
• VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
• CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
• VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
• IGRLIBJHDBWKNA-SYDPRGILSA-N (1r,3s)-cyclopent-4-ene-1,3-diol Chemical compound O[C@H]1C[C@@H](O)C=C1 IGRLIBJHDBWKNA-SYDPRGILSA-N 0.000 description 1
• RLMGYIOTPQVQJR-OLQVQODUSA-N (1s,3r)-cyclohexane-1,3-diol Chemical compound O[C@H]1CCC[C@@H](O)C1 RLMGYIOTPQVQJR-OLQVQODUSA-N 0.000 description 1
• NVEOJHBLYNJCKV-ICSRJNTNSA-N (1s,3s)-3-[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxycyclohexan-1-ol Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(O[C@@H]3C[C@@H](O)CCC3)=C12 NVEOJHBLYNJCKV-ICSRJNTNSA-N 0.000 description 1
• YTGXKUAETHMJKG-HKUYNNGSSA-N (1s,3s)-3-[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxycyclopentan-1-ol Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(O[C@@H]3C[C@@H](O)CC3)=C12 YTGXKUAETHMJKG-HKUYNNGSSA-N 0.000 description 1
• RLMGYIOTPQVQJR-WDSKDSINSA-N (1s,3s)-cyclohexane-1,3-diol Chemical compound O[C@H]1CCC[C@H](O)C1 RLMGYIOTPQVQJR-WDSKDSINSA-N 0.000 description 1
• NUUPJBRGQCEZSI-WHFBIAKZSA-N (1s,3s)-cyclopentane-1,3-diol Chemical compound O[C@H]1CC[C@H](O)C1 NUUPJBRGQCEZSI-WHFBIAKZSA-N 0.000 description 1
• QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
• NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 1
• DMYZJLOWGSRVKP-RTBURBONSA-N (2r,4r)-1-n-(4-chlorophenyl)-4-hydroxy-2-n-[4-(3-oxomorpholin-4-yl)phenyl]pyrrolidine-1,2-dicarboxamide Chemical compound N1([C@H](C[C@H](C1)O)C(=O)NC=1C=CC(=CC=1)N1C(COCC1)=O)C(=O)NC1=CC=C(Cl)C=C1 DMYZJLOWGSRVKP-RTBURBONSA-N 0.000 description 1
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
• ZXEIEKDGPVTZLD-NDEPHWFRSA-N (2s)-2-dodecylsulfanyl-n-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide Chemical compound O=C([C@@H](SCCCCCCCCCCCC)C=1C=CC=CC=1)NC1=CC(C)=C(O)C(C)=C1C ZXEIEKDGPVTZLD-NDEPHWFRSA-N 0.000 description 1
• LJCBAPRMNYSDOP-LVCYMWGESA-N (2s)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3s)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;hydron;chloride;pentahydrate Chemical compound O.O.O.O.O.Cl.C1N(C(=N)C)CC[C@@H]1OC1=CC=C([C@H](CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)C(O)=O)C=C1 LJCBAPRMNYSDOP-LVCYMWGESA-N 0.000 description 1
• BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
• YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
• RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 1
• METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
• KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
• KDBZSVVTOOTXNC-XNTDXEJSSA-N (e)-3-[3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenyl]prop-2-enoic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(NC=3C=C(\C=C\C(O)=O)C=CC=3)=C12 KDBZSVVTOOTXNC-XNTDXEJSSA-N 0.000 description 1
• DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
• UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
• BNOQIYXSYIBAPH-UHFFFAOYSA-N 1-(4-ethylphenyl)-2-hydroxy-2-phenylethanone Chemical compound C1=CC(CC)=CC=C1C(=O)C(O)C1=CC=CC=C1 BNOQIYXSYIBAPH-UHFFFAOYSA-N 0.000 description 1
• ZUCFGSAENWHFPO-UHFFFAOYSA-N 1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrate;hydrochloride Chemical compound O.Cl.CC(C)C=1C=C(N)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OCCCO)=C1 ZUCFGSAENWHFPO-UHFFFAOYSA-N 0.000 description 1
• PMGZJNCIQHGNLT-UHFFFAOYSA-N 1-[bis(2,2-dimethylpropanoyloxymethoxy)phosphoryl]-4-(3-phenoxyphenyl)butane-1-sulfonic acid Chemical compound CC(C)(C)C(=O)OCOP(=O)(OCOC(=O)C(C)(C)C)C(S(O)(=O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 PMGZJNCIQHGNLT-UHFFFAOYSA-N 0.000 description 1
• MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
• GUSVHVVOABZHAH-OPZWKQDFSA-N 1aw8p77hkj Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GUSVHVVOABZHAH-OPZWKQDFSA-N 0.000 description 1
• DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical class O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
• MGAXHFMCFLLMNG-UHFFFAOYSA-N 1h-pyrimidine-6-thione Chemical compound SC1=CC=NC=N1 MGAXHFMCFLLMNG-UHFFFAOYSA-N 0.000 description 1
• YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
• OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
• CASCTHHMARGRLB-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-n-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide;hydrochloride Chemical compound Cl.CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 CASCTHHMARGRLB-UHFFFAOYSA-N 0.000 description 1
• DEMLYXMVPJAVFU-UHFFFAOYSA-N 2-(chloromethyl)oxirane;2-methyl-1h-imidazole Chemical compound ClCC1CO1.CC1=NC=CN1 DEMLYXMVPJAVFU-UHFFFAOYSA-N 0.000 description 1
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
• SAFWGDRQYHBIIA-FPOVZHCZSA-N 2-[(1s,3s)-3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]cyclohexyl]oxyacetic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(N[C@@H]3C[C@H](CCC3)OCC(O)=O)=C12 SAFWGDRQYHBIIA-FPOVZHCZSA-N 0.000 description 1
• HQSRVYUCBOCBLY-XOOFNSLWSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2s,4r)-2-(4-chlorophenyl)-2-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CSC=4N(C=NN=4)C)(OC3)C=3C=CC(Cl)=CC=3)=CC=2)C=C1 HQSRVYUCBOCBLY-XOOFNSLWSA-N 0.000 description 1
• CMLUGNQVANVZHY-POURPWNDSA-N 2-[1-[2-[(3r,5s)-1-(3-acetyloxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-5h-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid Chemical compound COC1=CC=CC([C@@H]2C3=CC(Cl)=CC=C3N(CC(C)(C)COC(C)=O)C(=O)[C@@H](CC(=O)N3CCC(CC(O)=O)CC3)O2)=C1OC CMLUGNQVANVZHY-POURPWNDSA-N 0.000 description 1
• FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 description 1
• FHZGFOPXGAFFIW-UHFFFAOYSA-N 2-[3-(5-bromo-6-phenylfuro[2,3-d]pyrimidin-4-yl)oxycyclohexyl]oxyacetic acid Chemical compound BrC1=C(OC=2N=CN=C(C=21)OC1CC(CCC1)OCC(=O)O)C1=CC=CC=C1 FHZGFOPXGAFFIW-UHFFFAOYSA-N 0.000 description 1
• OKPLELMNYAAENZ-UHFFFAOYSA-N 2-[3-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=CC(NC=2C=3C(C=4C=CC=CC=4)=C(OC=3N=CN=2)C=2C=CC=CC=2)=C1 OKPLELMNYAAENZ-UHFFFAOYSA-N 0.000 description 1
• GKHIVNAUVKXIIY-UHFFFAOYSA-N 2-[3-[4-(1h-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-ylacetamide Chemical compound CC(C)NC(=O)COC1=CC=CC(C=2N=C3C=CC=CC3=C(NC=3C=C4C=NNC4=CC=3)N=2)=C1 GKHIVNAUVKXIIY-UHFFFAOYSA-N 0.000 description 1
• QBRBOPLRECYFHG-UHFFFAOYSA-N 2-[3-[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxyanilino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(OC=3C=C(NCC(O)=O)C=CC=3)=C12 QBRBOPLRECYFHG-UHFFFAOYSA-N 0.000 description 1
• FXEAJAVPPOTURV-UHFFFAOYSA-N 2-[3-[[5,6-bis(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]amino]phenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)C2=C(NC=3C=C(OCC(O)=O)C=CC=3)N=CN=C2O1 FXEAJAVPPOTURV-UHFFFAOYSA-N 0.000 description 1
• OZSSSKYYBFWQQY-UHFFFAOYSA-N 2-[3-[[5-(4-fluorophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=CC(NC=2C=3C(C=4C=CC(F)=CC=4)=C(OC=3N=CN=2)C=2C=CC=CC=2)=C1 OZSSSKYYBFWQQY-UHFFFAOYSA-N 0.000 description 1
• MTBQTYCYYOJDTP-UHFFFAOYSA-N 2-[3-[[5-(4-hydroxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=CC(NC=2C=3C(C=4C=CC(O)=CC=4)=C(OC=3N=CN=2)C=2C=CC=CC=2)=C1 MTBQTYCYYOJDTP-UHFFFAOYSA-N 0.000 description 1
• FFYRVLFNCCKRTI-UHFFFAOYSA-N 2-[3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenoxy]acetamide Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(NC=3C=C(OCC(N)=O)C=CC=3)=C12 FFYRVLFNCCKRTI-UHFFFAOYSA-N 0.000 description 1
• ISBSUPSGPCGQFO-UHFFFAOYSA-N 2-[3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(NC=3C=C(CC(O)=O)C=CC=3)=C12 ISBSUPSGPCGQFO-UHFFFAOYSA-N 0.000 description 1
• UOJMJBUYXYEPFX-UHFFFAOYSA-N 2-[4-(4-hydroxy-3-propan-2-ylphenoxy)-3,5-dimethylanilino]-2-oxoacetic acid Chemical compound C1=C(O)C(C(C)C)=CC(OC=2C(=CC(NC(=O)C(O)=O)=CC=2C)C)=C1 UOJMJBUYXYEPFX-UHFFFAOYSA-N 0.000 description 1
• TXIIZHHIOHVWJD-UHFFFAOYSA-N 2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindol-5-yl]acetic acid Chemical compound CC(C)(C)C(=O)NC1=C(C)C(CC(O)=O)=C(C)C2=C1N(CCCCCCCC)CC2 TXIIZHHIOHVWJD-UHFFFAOYSA-N 0.000 description 1
• NZKANSJXJCILHS-UHFFFAOYSA-N 2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl]methyl]-3h-isoindol-1-one;dihydrate;hydrochloride Chemical compound O.O.Cl.C1=CC(F)=CC=C1C(=O)CN1CCC(CN2C(C3=CC=CC=C3C2)=O)CC1 NZKANSJXJCILHS-UHFFFAOYSA-N 0.000 description 1
• QHVBWSIFLCIXBD-UHFFFAOYSA-N 2-[[2-[3-(diaminomethylidene)-6-oxocyclohexa-1,4-dien-1-yl]oxy-3,5-difluoro-6-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]pyridin-4-yl]-methylamino]acetic acid Chemical compound N=1C(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=C(F)C(N(CC(O)=O)C)=C(F)C=1OC1=CC(=C(N)N)C=CC1=O QHVBWSIFLCIXBD-UHFFFAOYSA-N 0.000 description 1
• BPFMLOQVCKVCAT-UHFFFAOYSA-N 2-amino-4,5-diphenylfuran-3-carbonitrile Chemical compound N#CC1=C(N)OC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 BPFMLOQVCKVCAT-UHFFFAOYSA-N 0.000 description 1
• ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
• SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
• RMBWXPGIEKXSIW-UHFFFAOYSA-N 2-phenylfuro[2,3-d]pyrimidine Chemical compound N1=C2OC=CC2=CN=C1C1=CC=CC=C1 RMBWXPGIEKXSIW-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• AUYYCJSJGJYCDS-UHFFFAOYSA-N 2/3/6893 Natural products IC1=CC(CC(N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-UHFFFAOYSA-N 0.000 description 1
• SBHFVSXLYOBZKD-UHFFFAOYSA-N 3-(3-aminophenyl)propanoic acid Chemical compound NC1=CC=CC(CCC(O)=O)=C1 SBHFVSXLYOBZKD-UHFFFAOYSA-N 0.000 description 1
• QPKQAUZXDJEZNF-NRFANRHFSA-N 3-[(3s)-3-[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxypiperidin-1-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(O[C@@H]3CN(CCC(O)=O)CCC3)=C12 QPKQAUZXDJEZNF-NRFANRHFSA-N 0.000 description 1
• RNTQAZDKUJZVCR-UHFFFAOYSA-N 3-[4-[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxyphenyl]propanoic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(OC=3C=CC(CCC(O)=O)=CC=3)=C12 RNTQAZDKUJZVCR-UHFFFAOYSA-N 0.000 description 1
• CBQUHNKFIBKZDY-UHFFFAOYSA-N 3-[5-(4-ethylphenyl)-6-(2-fluorophenyl)furo[2,3-d]pyrimidin-4-yl]oxycyclohexan-1-ol Chemical compound C1=CC(CC)=CC=C1C1=C(C=2C(=CC=CC=2)F)OC2=NC=NC(OC3CC(O)CCC3)=C12 CBQUHNKFIBKZDY-UHFFFAOYSA-N 0.000 description 1
• CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 1
• 229940018563 3-aminophenol Drugs 0.000 description 1
• NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
• RTZZCYNQPHTPPL-UHFFFAOYSA-N 3-nitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1 RTZZCYNQPHTPPL-UHFFFAOYSA-N 0.000 description 1
• TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 1
• DUFGYCAXVIUXIP-UHFFFAOYSA-N 4,6-dihydroxypyrimidine Chemical compound OC1=CC(O)=NC=N1 DUFGYCAXVIUXIP-UHFFFAOYSA-N 0.000 description 1
• BMGIMCRPRTWLTE-UHFFFAOYSA-N 4-(2-nitrophenyl)butanoic acid Chemical compound OC(=O)CCCC1=CC=CC=C1[N+]([O-])=O BMGIMCRPRTWLTE-UHFFFAOYSA-N 0.000 description 1
• RBHLFWNKEWLHBP-UHFFFAOYSA-N 4-(4-aminophenyl)butanoic acid Chemical compound NC1=CC=C(CCCC(O)=O)C=C1 RBHLFWNKEWLHBP-UHFFFAOYSA-N 0.000 description 1
• NOBZETMXGVAWIM-UHFFFAOYSA-N 4-[(2-carbamimidoyl-3,4-dihydro-1h-isoquinolin-7-yl)oxymethyl]-1-pyridin-4-ylpiperidine-4-carboxylic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=C2CN(C(=N)N)CCC2=CC=C1OCC(CC1)(C(O)=O)CCN1C1=CC=NC=C1 NOBZETMXGVAWIM-UHFFFAOYSA-N 0.000 description 1
• CQNURHODYANJJN-RUZDIDTESA-N 4-[(3r)-1-benzylpiperidin-3-yl]oxy-5-(4-ethylphenyl)-6-(2-fluorophenyl)furo[2,3-d]pyrimidine Chemical compound C1=CC(CC)=CC=C1C1=C(C=2C(=CC=CC=2)F)OC2=NC=NC(O[C@H]3CN(CC=4C=CC=CC=4)CCC3)=C12 CQNURHODYANJJN-RUZDIDTESA-N 0.000 description 1
• YXADHVDKQVDZFX-XMMPIXPASA-N 4-[(3r)-1-benzylpiperidin-3-yl]oxy-6-(2-fluorophenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC=CC=2)F)OC2=NC=NC(O[C@H]3CN(CC=4C=CC=CC=4)CCC3)=C12 YXADHVDKQVDZFX-XMMPIXPASA-N 0.000 description 1
• PSXMPWUMJAZRIF-UHFFFAOYSA-N 4-[2-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenyl]butanoic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(NC=3C(=CC=CC=3)CCCC(O)=O)=C12 PSXMPWUMJAZRIF-UHFFFAOYSA-N 0.000 description 1
• DVCUHHGOEJQWRQ-UHFFFAOYSA-N 4-[2-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxymethyl]pyrrolidin-1-yl]butanenitrile Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(OCC3N(CCC3)CCCC#N)=C12 DVCUHHGOEJQWRQ-UHFFFAOYSA-N 0.000 description 1
• RBGOHHBSCQMOMI-UHFFFAOYSA-N 4-[3-[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxypiperidin-1-yl]butanenitrile Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(OC3CN(CCCC#N)CCC3)=C12 RBGOHHBSCQMOMI-UHFFFAOYSA-N 0.000 description 1
• LAZUARFQDRZACO-UHFFFAOYSA-N 4-[4-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenyl]butanoic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(NC=3C=CC(CCCC(O)=O)=CC=3)=C12 LAZUARFQDRZACO-UHFFFAOYSA-N 0.000 description 1
• 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
• OCPYCSFTSXTKEX-UHFFFAOYSA-N 4-chloro-5,6-bis(4-methoxyphenyl)furo[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)C2=C(Cl)N=CN=C2O1 OCPYCSFTSXTKEX-UHFFFAOYSA-N 0.000 description 1
• DZCDERJEEHCRHG-UHFFFAOYSA-N 4-chloro-5,6-diphenylfuro[2,3-d]pyrimidine Chemical compound C1=2C(Cl)=NC=NC=2OC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 DZCDERJEEHCRHG-UHFFFAOYSA-N 0.000 description 1
• DXKBIBAPPDRHAG-UHFFFAOYSA-N 4-chloro-5-(4-ethylphenyl)-6-phenylfuro[2,3-d]pyrimidine Chemical compound C1=CC(CC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(Cl)=C12 DXKBIBAPPDRHAG-UHFFFAOYSA-N 0.000 description 1
• MDROXXBYOBFYFK-UHFFFAOYSA-N 4-chloro-6-phenylfuro[3,2-c]pyridine Chemical compound C=1C=2OC=CC=2C(Cl)=NC=1C1=CC=CC=C1 MDROXXBYOBFYFK-UHFFFAOYSA-N 0.000 description 1
• KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 1
• OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
• YKFDSHYUHORXQW-UHFFFAOYSA-N 5,6-diphenylfuro[2,3-d]pyrimidine Chemical compound C1=CC=CC=C1C1=C(C=2C=CC=CC=2)C2=CN=CN=C2O1 YKFDSHYUHORXQW-UHFFFAOYSA-N 0.000 description 1
• VOALZUQYGZLLAG-UHFFFAOYSA-N 5-(4-methoxyphenyl)-6-phenyl-n-[3-(2h-tetrazol-5-ylmethoxy)phenyl]furo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(NC=3C=C(OCC=4NN=NN=4)C=CC=3)=C12 VOALZUQYGZLLAG-UHFFFAOYSA-N 0.000 description 1
• OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
• FGBVAWOZJCARLU-UHFFFAOYSA-N 5-[[3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenyl]methyl]-3h-1,3,4-oxadiazol-2-one Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(NC=3C=C(CC=4OC(=O)NN=4)C=CC=3)=C12 FGBVAWOZJCARLU-UHFFFAOYSA-N 0.000 description 1
• AZPRBKCYXBNTJR-QGZVFWFLSA-N 6-(2-fluorophenyl)-5-(4-methoxyphenyl)-4-[(3r)-piperidin-3-yl]oxyfuro[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC=CC=2)F)OC2=NC=NC(O[C@H]3CNCCC3)=C12 AZPRBKCYXBNTJR-QGZVFWFLSA-N 0.000 description 1
• VPSJNYUMVGPTAQ-UNTBIKODSA-N 6-(2-fluorophenyl)-5-(4-methoxyphenyl)-4-[(3r)-piperidin-3-yl]oxyfuro[2,3-d]pyrimidine;formic acid Chemical compound OC=O.C1=CC(OC)=CC=C1C1=C(C=2C(=CC=CC=2)F)OC2=NC=NC(O[C@H]3CNCCC3)=C12 VPSJNYUMVGPTAQ-UNTBIKODSA-N 0.000 description 1
• YPFSJOQNFQDNIC-UHFFFAOYSA-N 6-(4-bromophenyl)-4-chloro-5-phenylfuro[2,3-d]pyrimidine Chemical compound C1=2C(Cl)=NC=NC=2OC(C=2C=CC(Br)=CC=2)=C1C1=CC=CC=C1 YPFSJOQNFQDNIC-UHFFFAOYSA-N 0.000 description 1
• DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
• KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
• PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 1
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
• 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 239000002083 C09CA01 - Losartan Substances 0.000 description 1
• 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
• 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
• 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
• UFKDEYHYVBHPBB-UHFFFAOYSA-N CN1CCOCC1.C(C1=CC=CC=C1)NCC1=CC=CC=C1 Chemical compound CN1CCOCC1.C(C1=CC=CC=C1)NCC1=CC=CC=C1 UFKDEYHYVBHPBB-UHFFFAOYSA-N 0.000 description 1
• 108090000312 Calcium Channels Proteins 0.000 description 1
• 102000003922 Calcium Channels Human genes 0.000 description 1
• JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
• 206010008190 Cerebrovascular accident Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
• 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 1
• 229920001268 Cholestyramine Polymers 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 229920002905 Colesevelam Polymers 0.000 description 1
• 229920002911 Colestipol Polymers 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
• 108010061435 Enalapril Proteins 0.000 description 1
• YARKMNAWFIMDKV-UHFFFAOYSA-N Epanolol Chemical compound C=1C=CC=C(C#N)C=1OCC(O)CNCCNC(=O)CC1=CC=C(O)C=C1 YARKMNAWFIMDKV-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108010078321 Guanylate Cyclase Proteins 0.000 description 1
• 102000014469 Guanylate cyclase Human genes 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 1
• 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
• 101000874160 Homo sapiens Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 description 1
• 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
• 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
• KOZFSFOOLUUIGY-SOLYNIJKSA-N K-252a Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@](C(=O)OC)(O)[C@]4(C)O1 KOZFSFOOLUUIGY-SOLYNIJKSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 229940086609 Lipase inhibitor Drugs 0.000 description 1
• 108010007859 Lisinopril Proteins 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
• 101000692644 Mus musculus Prostacyclin receptor Proteins 0.000 description 1
• XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 description 1
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
• AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
• NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
• UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
• 239000000006 Nitroglycerin Substances 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
• 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 description 1
• 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• 102000006447 Phospholipases A2 Human genes 0.000 description 1
• 108010058864 Phospholipases A2 Proteins 0.000 description 1
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 101710170814 Prostacyclin receptor Proteins 0.000 description 1
• 102100026476 Prostacyclin receptor Human genes 0.000 description 1
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 101000692657 Rattus norvegicus Prostacyclin receptor Proteins 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 108091006614 SLC10A2 Proteins 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 208000007718 Stable Angina Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 244000028419 Styrax benzoin Species 0.000 description 1
• 235000000126 Styrax benzoin Nutrition 0.000 description 1
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 235000008411 Sumatra benzointree Nutrition 0.000 description 1
• 238000006069 Suzuki reaction reaction Methods 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
• 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
• 229940122388 Thrombin inhibitor Drugs 0.000 description 1
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
• VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
• XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 1
• 208000007814 Unstable Angina Diseases 0.000 description 1
• SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
• IJDYOKVVRXZCFD-NKWVEPMBSA-N [(1s,4r)-4-hydroxycyclopent-2-en-1-yl] acetate Chemical compound CC(=O)O[C@H]1C[C@@H](O)C=C1 IJDYOKVVRXZCFD-NKWVEPMBSA-N 0.000 description 1
• AEBIBBWVNCPTNL-UHFFFAOYSA-N [1-(hydroxymethyl)cyclobutyl]methanol Chemical compound OCC1(CO)CCC1 AEBIBBWVNCPTNL-UHFFFAOYSA-N 0.000 description 1
• SAGXTDPKLVNZRB-UHFFFAOYSA-N [1-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxymethyl]cyclobutyl]methanol Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(OCC3(CO)CCC3)=C12 SAGXTDPKLVNZRB-UHFFFAOYSA-N 0.000 description 1
• MNLVCBKWEVXHGE-UHFFFAOYSA-N [CH]1[CH]CC[CH]1 Chemical group [CH]1[CH]CC[CH]1 MNLVCBKWEVXHGE-UHFFFAOYSA-N 0.000 description 1
• OLVCTBRABXEFAA-UHFFFAOYSA-N [Pt+3]=O Chemical compound [Pt+3]=O OLVCTBRABXEFAA-UHFFFAOYSA-N 0.000 description 1
• 229960000446 abciximab Drugs 0.000 description 1
• RBYGDVHOECIAFC-UHFFFAOYSA-L acetonitrile;palladium(2+);dichloride Chemical compound [Cl-].[Cl-].[Pd+2].CC#N.CC#N RBYGDVHOECIAFC-UHFFFAOYSA-L 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 238000010306 acid treatment Methods 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 229950000221 adaprolol Drugs 0.000 description 1
• IPGLIOFIFLXLKR-AXYNENQYSA-N adaprolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CC(=O)OCCC1(C2)C[C@@H](C3)C[C@H]2C[C@@H]3C1 IPGLIOFIFLXLKR-AXYNENQYSA-N 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 239000003121 adenosine kinase inhibitor Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 229960004601 aliskiren Drugs 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229960002213 alprenolol Drugs 0.000 description 1
• PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 229960000528 amlodipine Drugs 0.000 description 1
• ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000003698 antivitamin K Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 239000012300 argon atmosphere Substances 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 229960002274 atenolol Drugs 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 229960005370 atorvastatin Drugs 0.000 description 1
• 230000001746 atrial effect Effects 0.000 description 1
• 229950010046 avasimibe Drugs 0.000 description 1
• RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
• 229910001863 barium hydroxide Inorganic materials 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960002130 benzoin Drugs 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N benzyl-alpha-carboxylic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
• 229960002890 beraprost Drugs 0.000 description 1
• CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 description 1
• 229960004324 betaxolol Drugs 0.000 description 1
• CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 229960002781 bisoprolol Drugs 0.000 description 1
• VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
• OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
• 229960001500 bivalirudin Drugs 0.000 description 1
• 108010055460 bivalirudin Proteins 0.000 description 1
• 239000007844 bleaching agent Substances 0.000 description 1
• 230000031709 bromination Effects 0.000 description 1
• 238000005893 bromination reaction Methods 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• DNPRVXJGNANVCZ-UHFFFAOYSA-N bromo(nitro)methane Chemical compound [O-][N+](=O)CBr DNPRVXJGNANVCZ-UHFFFAOYSA-N 0.000 description 1
• 125000004799 bromophenyl group Chemical group 0.000 description 1
• 229950005341 bucindolol Drugs 0.000 description 1
• 229960000330 bupranolol Drugs 0.000 description 1
• HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
• 229960000932 candesartan Drugs 0.000 description 1
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
• 229960000830 captopril Drugs 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 229960001222 carteolol Drugs 0.000 description 1
• LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
• 229960004195 carvedilol Drugs 0.000 description 1
• NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 229960002320 celiprolol Drugs 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 229960005110 cerivastatin Drugs 0.000 description 1
• SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• IDDDVXIUIXWAGJ-LJDSMOQUSA-N chembl1605605 Chemical compound Cl.Cl.C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-LJDSMOQUSA-N 0.000 description 1
• 238000000451 chemical ionisation Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
• 229960003009 clopidogrel Drugs 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
• 229960002604 colestipol Drugs 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000012230 colorless oil Substances 0.000 description 1
• 238000007887 coronary angioplasty Methods 0.000 description 1
• 229960000956 coumarin Drugs 0.000 description 1
• 235000001671 coumarin Nutrition 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 150000003983 crown ethers Chemical class 0.000 description 1
• MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• PDXRQENMIVHKPI-UHFFFAOYSA-N cyclohexane-1,1-diol Chemical compound OC1(O)CCCCC1 PDXRQENMIVHKPI-UHFFFAOYSA-N 0.000 description 1
• GEQHKFFSPGPGLN-UHFFFAOYSA-N cyclohexane-1,3-diamine Chemical compound NC1CCCC(N)C1 GEQHKFFSPGPGLN-UHFFFAOYSA-N 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 229960002887 deanol Drugs 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 229960005227 delapril Drugs 0.000 description 1
• WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• CARVNSROHCBVAO-BUGJESOBSA-N depelestat Chemical compound O=C([C@H](C(C)C)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@H]4N(CCC4)C(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC3=O)C(C)C)CSSC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(C)C)[C@@H](C)CC)C(C)C)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)N1CCC[C@H]1C(O)=O CARVNSROHCBVAO-BUGJESOBSA-N 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 229960001767 dextrothyroxine Drugs 0.000 description 1
• 125000004663 dialkyl amino group Chemical group 0.000 description 1
• 229940120124 dichloroacetate Drugs 0.000 description 1
• JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• FPUQGCOBYOXAED-UHFFFAOYSA-N diethyl 2-[[2-[3-(dimethylcarbamoyl)-4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]acetyl]oxymethyl]-2-phenylpropanedioate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)(C(=O)OCC)COC(=O)CC(C=C1C(=O)N(C)C)=CC=C1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 FPUQGCOBYOXAED-UHFFFAOYSA-N 0.000 description 1
• HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
• 229960004166 diltiazem Drugs 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
• 229960002768 dipyridamole Drugs 0.000 description 1
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
• SPBWMYPZWNFWES-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide;dihydrate Chemical compound O.O.[Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N SPBWMYPZWNFWES-UHFFFAOYSA-N 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 230000001882 diuretic effect Effects 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 229960000622 edoxaban Drugs 0.000 description 1
• PSMMNJNZVZZNOI-SJILXJHISA-N edoxaban tosylate hydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 PSMMNJNZVZZNOI-SJILXJHISA-N 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 229950005925 eflucimibe Drugs 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• XFLQIRAKKLNXRQ-UUWRZZSWSA-N elobixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C=3C=CC=CC=3)C=C2S(=O)(=O)CC(CCCC)(CCCC)CN1C1=CC=CC=C1 XFLQIRAKKLNXRQ-UUWRZZSWSA-N 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
• 229960000873 enalapril Drugs 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 239000002308 endothelin receptor antagonist Substances 0.000 description 1
• 230000037149 energy metabolism Effects 0.000 description 1
• 229960002711 epanolol Drugs 0.000 description 1
• 229960001208 eplerenone Drugs 0.000 description 1
• JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
• KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• 229960003745 esmolol Drugs 0.000 description 1
• AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
• 238000010931 ester hydrolysis Methods 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• FUBBWDWIGBTUPQ-UHFFFAOYSA-N ethyl 2-[4-[3-[(4-fluorophenyl)-hydroxymethyl]-4-hydroxyphenoxy]-3,5-dimethylanilino]-2-oxoacetate Chemical compound CC1=CC(NC(=O)C(=O)OCC)=CC(C)=C1OC1=CC=C(O)C(C(O)C=2C=CC(F)=CC=2)=C1 FUBBWDWIGBTUPQ-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
• 229960000815 ezetimibe Drugs 0.000 description 1
• 229960002435 fasudil Drugs 0.000 description 1
• LFVPBERIVUNMGV-UHFFFAOYSA-N fasudil hydrochloride Chemical compound Cl.C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 LFVPBERIVUNMGV-UHFFFAOYSA-N 0.000 description 1
• 229950010034 fidexaban Drugs 0.000 description 1
• 229960003765 fluvastatin Drugs 0.000 description 1
• KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
• 229960001318 fondaparinux Drugs 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 229960002490 fosinopril Drugs 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• JPIPZNJBXFDXHH-UHFFFAOYSA-N furo[2,3-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=C1C=CO2 JPIPZNJBXFDXHH-UHFFFAOYSA-N 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 229960003883 furosemide Drugs 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 238000004817 gas chromatography Methods 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• 238000005227 gel permeation chromatography Methods 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 229960003711 glyceryl trinitrate Drugs 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000003119 guanylate cyclase activator Substances 0.000 description 1
• 235000019382 gum benzoic Nutrition 0.000 description 1
• 210000002064 heart cell Anatomy 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 239000012456 homogeneous solution Substances 0.000 description 1
• 102000052502 human ELANE Human genes 0.000 description 1
• 102000045360 human SDHB Human genes 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 150000004678 hydrides Chemical class 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 229960002240 iloprost Drugs 0.000 description 1
• HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 239000001023 inorganic pigment Substances 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
• 229960000201 isosorbide dinitrate Drugs 0.000 description 1
• YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
• 229960003827 isosorbide mononitrate Drugs 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 229960001632 labetalol Drugs 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229950005241 landiolol Drugs 0.000 description 1
• WMDSZGFJQKSLLH-RBBKRZOGSA-N landiolol Chemical compound O1C(C)(C)OC[C@H]1COC(=O)CCC(C=C1)=CC=C1OC[C@@H](O)CNCCNC(=O)N1CCOCC1 WMDSZGFJQKSLLH-RBBKRZOGSA-N 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 229960002394 lisinopril Drugs 0.000 description 1
• CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
• DTMCOMZUESDMSN-UHFFFAOYSA-N lithium;trimethylsilicon Chemical compound [Li][Si](C)(C)C DTMCOMZUESDMSN-UHFFFAOYSA-N 0.000 description 1
• 229960003566 lomitapide Drugs 0.000 description 1
• QKVKOFVWUHNEBX-UHFFFAOYSA-N lomitapide mesylate Chemical compound CS(O)(=O)=O.C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCC(F)(F)F)CCCCN(CC1)CCC1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 QKVKOFVWUHNEBX-UHFFFAOYSA-N 0.000 description 1
• 229960004773 losartan Drugs 0.000 description 1
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• 239000003055 low molecular weight heparin Substances 0.000 description 1
• 229940127215 low-molecular weight heparin Drugs 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 229950008446 melinamide Drugs 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 108020004084 membrane receptors Proteins 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 229960003134 mepindolol Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
• HZVBUTMEFLKNJQ-UHFFFAOYSA-N methyl 2-[3-[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxyanilino]acetate Chemical compound COC(=O)CNC1=CC=CC(OC=2C=3C(C=4C=CC(OC)=CC=4)=C(OC=3N=CN=2)C=2C=CC=CC=2)=C1 HZVBUTMEFLKNJQ-UHFFFAOYSA-N 0.000 description 1
• GWASURZYAOOJAP-UHFFFAOYSA-N methyl 2-[3-[[5-(4-fluorophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenoxy]acetate Chemical compound COC(=O)COC1=CC=CC(NC=2C=3C(C=4C=CC(F)=CC=4)=C(OC=3N=CN=2)C=2C=CC=CC=2)=C1 GWASURZYAOOJAP-UHFFFAOYSA-N 0.000 description 1
• KFKXSMSQHIOMSO-UHFFFAOYSA-N methyl 2-oxoacetate Chemical compound COC(=O)C=O KFKXSMSQHIOMSO-UHFFFAOYSA-N 0.000 description 1
• UPXYAKKZOLELBU-UHFFFAOYSA-N methyl 3-(3-aminophenyl)propanoate;hydrochloride Chemical compound Cl.COC(=O)CCC1=CC=CC(N)=C1 UPXYAKKZOLELBU-UHFFFAOYSA-N 0.000 description 1
• XRAMJHXWXCMGJM-UHFFFAOYSA-N methyl 3-(4-hydroxyphenyl)propionate Chemical compound COC(=O)CCC1=CC=C(O)C=C1 XRAMJHXWXCMGJM-UHFFFAOYSA-N 0.000 description 1
• VRVTTXSPFDJLLY-UHFFFAOYSA-N methyl 3-[3-[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]oxypiperidin-1-yl]propanoate Chemical compound C1N(CCC(=O)OC)CCCC1OC1=NC=NC2=C1C(C=1C=CC(OC)=CC=1)=C(C=1C=CC=CC=1)O2 VRVTTXSPFDJLLY-UHFFFAOYSA-N 0.000 description 1
• RPKRGKMXEAFIOQ-UHFFFAOYSA-N methyl 4-(2-aminophenyl)butanoate Chemical compound COC(=O)CCCC1=CC=CC=C1N RPKRGKMXEAFIOQ-UHFFFAOYSA-N 0.000 description 1
• CLKHQWJXESOLCJ-UHFFFAOYSA-N methyl 4-(4-aminophenyl)butanoate Chemical compound COC(=O)CCCC1=CC=C(N)C=C1 CLKHQWJXESOLCJ-UHFFFAOYSA-N 0.000 description 1
• OFKANAADLNCVPH-UHFFFAOYSA-N methyl 4-(4-aminophenyl)butanoate;hydrochloride Chemical compound Cl.COC(=O)CCCC1=CC=C(N)C=C1 OFKANAADLNCVPH-UHFFFAOYSA-N 0.000 description 1
• HJHAGQSFTYBDOC-SECBINFHSA-N methyl 4-[(3r)-3-hydroxypiperidin-1-yl]butanoate Chemical compound COC(=O)CCCN1CCC[C@@H](O)C1 HJHAGQSFTYBDOC-SECBINFHSA-N 0.000 description 1
• OESNDCWFYAJEOS-MRXNPFEDSA-N methyl 4-[(3r)-3-phenylmethoxypiperidin-1-yl]butanoate Chemical compound C1N(CCCC(=O)OC)CCC[C@H]1OCC1=CC=CC=C1 OESNDCWFYAJEOS-MRXNPFEDSA-N 0.000 description 1
• WQFWHGQXLRMVAX-UHFFFAOYSA-N methyl 4-[3-(5-bromo-6-phenylfuro[2,3-d]pyrimidin-4-yl)oxypiperidin-1-yl]butanoate Chemical compound C1N(CCCC(=O)OC)CCCC1OC1=NC=NC2=C1C(Br)=C(C=1C=CC=CC=1)O2 WQFWHGQXLRMVAX-UHFFFAOYSA-N 0.000 description 1
• OLVGFJCJUZLULT-UHFFFAOYSA-N methyl 4-[4-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenyl]butanoate Chemical compound C1=CC(CCCC(=O)OC)=CC=C1NC1=NC=NC2=C1C(C=1C=CC(OC)=CC=1)=C(C=1C=CC=CC=1)O2 OLVGFJCJUZLULT-UHFFFAOYSA-N 0.000 description 1
• 229960002704 metipranolol Drugs 0.000 description 1
• BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 description 1
• 229960002237 metoprolol Drugs 0.000 description 1
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000002395 mineralocorticoid Substances 0.000 description 1
• 239000002394 mineralocorticoid antagonist Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
• 229960004027 molsidomine Drugs 0.000 description 1
• 239000012452 mother liquor Substances 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• BXQDWPXPKVWDGU-LLVKDONJSA-N n-[(1r)-1-phenylethyl]but-3-en-1-amine Chemical compound C=CCCN[C@H](C)C1=CC=CC=C1 BXQDWPXPKVWDGU-LLVKDONJSA-N 0.000 description 1
• NSRBCQCXZAYQHF-UHFFFAOYSA-N n-[[tert-butylimino-bis[[tris(dimethylamino)-$l^{5}-phosphanylidene]amino]-$l^{5}-phosphanyl]imino-bis(dimethylamino)-$l^{5}-phosphanyl]-n-methylmethanamine Chemical compound CN(C)P(N(C)C)(N(C)C)=NP(=NC(C)(C)C)(N=P(N(C)C)(N(C)C)N(C)C)N=P(N(C)C)(N(C)C)N(C)C NSRBCQCXZAYQHF-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004718 n-hexylthio group Chemical group C(CCCCC)S* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229960004255 nadolol Drugs 0.000 description 1
• VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
• YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 229920005615 natural polymer Polymers 0.000 description 1
• 229960000619 nebivolol Drugs 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
• 229960001597 nifedipine Drugs 0.000 description 1
• 125000002560 nitrile group Chemical group 0.000 description 1
• 238000010641 nitrile hydrolysis reaction Methods 0.000 description 1
• MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 150000002902 organometallic compounds Chemical class 0.000 description 1
• AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
• 229960001243 orlistat Drugs 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 229960004570 oxprenolol Drugs 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 229950003510 pactimibe Drugs 0.000 description 1
• LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
• VWMZIGBYZQUQOA-QEEMJVPDSA-N pamaqueside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC(=O)[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VWMZIGBYZQUQOA-QEEMJVPDSA-N 0.000 description 1
• 229950005482 pamaqueside Drugs 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229960002035 penbutolol Drugs 0.000 description 1
• KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
• RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
• 229960002582 perindopril Drugs 0.000 description 1
• 230000003836 peripheral circulation Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 239000003444 phase transfer catalyst Substances 0.000 description 1
• LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
• 229960003424 phenylacetic acid Drugs 0.000 description 1
• 239000003279 phenylacetic acid Substances 0.000 description 1
• NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
• 150000003906 phosphoinositides Chemical class 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
• 229960002508 pindolol Drugs 0.000 description 1
• JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 1
• 229960005095 pioglitazone Drugs 0.000 description 1
• DVMSBIVGIAGNNI-UHFFFAOYSA-N piperidin-1-ylcarbamic acid Chemical compound OC(=O)NN1CCCCC1 DVMSBIVGIAGNNI-UHFFFAOYSA-N 0.000 description 1
• 229960002797 pitavastatin Drugs 0.000 description 1
• VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 235000015497 potassium bicarbonate Nutrition 0.000 description 1
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
• 239000011736 potassium bicarbonate Substances 0.000 description 1
• 239000011698 potassium fluoride Substances 0.000 description 1
• 235000003270 potassium fluoride Nutrition 0.000 description 1
• NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
• 229910000105 potassium hydride Inorganic materials 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 229960002965 pravastatin Drugs 0.000 description 1
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
• IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
• 229960001289 prazosin Drugs 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 108010064377 prostacyclin synthetase Proteins 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 229960003401 ramipril Drugs 0.000 description 1
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
• 229960000213 ranolazine Drugs 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000003087 receptor blocking agent Substances 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
• GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
• 229960001755 resorcinol Drugs 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• ITDJKCJYYAQMRO-UHFFFAOYSA-L rhodium(2+);diacetate Chemical compound [Rh+2].CC([O-])=O.CC([O-])=O ITDJKCJYYAQMRO-UHFFFAOYSA-L 0.000 description 1
• SVOOVMQUISJERI-UHFFFAOYSA-K rhodium(3+);triacetate Chemical compound [Rh+3].CC([O-])=O.CC([O-])=O.CC([O-])=O SVOOVMQUISJERI-UHFFFAOYSA-K 0.000 description 1
• 229960001148 rivaroxaban Drugs 0.000 description 1
• KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• 229960000672 rosuvastatin Drugs 0.000 description 1
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 229960003310 sildenafil Drugs 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• BTGNGJJLZOIYID-UHFFFAOYSA-N sivelestat Chemical compound C1=CC(OC(=O)C(C)(C)C)=CC=C1S(=O)(=O)NC1=CC=CC=C1C(=O)NCC(O)=O BTGNGJJLZOIYID-UHFFFAOYSA-N 0.000 description 1
• 229950009343 sivelestat Drugs 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 229940083618 sodium nitroprusside Drugs 0.000 description 1
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 229960002370 sotalol Drugs 0.000 description 1
• ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 229960002256 spironolactone Drugs 0.000 description 1
• LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
• 229940031439 squalene Drugs 0.000 description 1
• TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000001300 stimulation of adenylate cyclase Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
• HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
• 150000003460 sulfonic acids Chemical class 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 229960000835 tadalafil Drugs 0.000 description 1
• IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229960005187 telmisartan Drugs 0.000 description 1
• RJJQZPLJQHVACE-VWNXMTODSA-N tert-butyl 2-[(1s,3r)-3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]cyclohexyl]oxyacetate Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(N[C@H]3C[C@H](CCC3)OCC(=O)OC(C)(C)C)=C12 RJJQZPLJQHVACE-VWNXMTODSA-N 0.000 description 1
• SFVQCCABMBWKMW-UWVGGRQHSA-N tert-butyl 2-[(1s,3s)-3-aminocyclohexyl]oxyacetate Chemical compound CC(C)(C)OC(=O)CO[C@H]1CCC[C@H](N)C1 SFVQCCABMBWKMW-UWVGGRQHSA-N 0.000 description 1
• XMROBJCWHFYGRW-CHWSQXEVSA-N tert-butyl 2-[(1s,4s)-4-(1,3-dioxoisoindol-2-yl)cyclopent-2-en-1-yl]oxyacetate Chemical compound C1=C[C@@H](OCC(=O)OC(C)(C)C)C[C@@H]1N1C(=O)C2=CC=CC=C2C1=O XMROBJCWHFYGRW-CHWSQXEVSA-N 0.000 description 1
• XBBGZUOEDLBLSQ-UHFFFAOYSA-N tert-butyl 2-[3-(5-bromo-6-phenylfuro[2,3-d]pyrimidin-4-yl)oxycyclohexyl]oxyacetate Chemical compound C1C(OCC(=O)OC(C)(C)C)CCCC1OC1=NC=NC2=C1C(Br)=C(C=1C=CC=CC=1)O2 XBBGZUOEDLBLSQ-UHFFFAOYSA-N 0.000 description 1
• UIJXHKXIOCDSEB-UHFFFAOYSA-N tert-butyl 3-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(O)C1 UIJXHKXIOCDSEB-UHFFFAOYSA-N 0.000 description 1
• 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• FRHOQDDDDFBHGW-UHFFFAOYSA-N tert-butyl n-piperidin-1-ylcarbamate Chemical compound CC(C)(C)OC(=O)NN1CCCCC1 FRHOQDDDDFBHGW-UHFFFAOYSA-N 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 239000003868 thrombin inhibitor Substances 0.000 description 1
• 230000009424 thromboembolic effect Effects 0.000 description 1
• 230000002537 thrombolytic effect Effects 0.000 description 1
• PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
• 229960005001 ticlopidine Drugs 0.000 description 1
• 229960004605 timolol Drugs 0.000 description 1
• 229950004437 tiqueside Drugs 0.000 description 1
• COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
• 229960003425 tirofiban Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 229960005032 treprostinil Drugs 0.000 description 1
• PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
• 229960001177 trimetazidine Drugs 0.000 description 1
• JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
• 229960004699 valsartan Drugs 0.000 description 1
• 229960002381 vardenafil Drugs 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 239000005526 vasoconstrictor agent Substances 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 229960001722 verapamil Drugs 0.000 description 1
• 229940019333 vitamin k antagonists Drugs 0.000 description 1
• ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 description 1
• 229960001522 ximelagatran Drugs 0.000 description 1
• 229940102001 zinc bromide Drugs 0.000 description 1